CDK9 and mantle cell lymphoma: A recent report discusses transcriptional reprogramming via CDK9 in IR MCL [86], and another report shows that EZH1/2 inhibition overcomes ibrutinib resistance in MCL primarily by up-regulating CDKN1C [79].